Related Experiment Video

Updated: Jun 11, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

[Therapy of hyperglycemia and risk of ischemic heart disease: 2010]

Jirí Charvát1, Milan Kvapil

  • 1Univerzita Karlova v Praze, 2. lékarská fakulta, Interní klinika FN Motol.

Casopis Lekaru Ceskych
|July 16, 2010
PubMed

Insights

Diabetic patients have a high prevalence of coronary artery diseases. Managing hyperglycemia, dyslipidemia, and hypertension can prevent cardiovascular complications in these individuals.

Area of Science:

  • Cardiology
  • Endocrinology
  • Diabetology

Background:

  • Coronary artery diseases (CAD) represent a significant health concern.
  • Diabetic patients exhibit a disproportionately high prevalence of CAD.
  • Elevated glycosylated hemoglobin levels correlate with increased cardiovascular risk in diabetes.

Purpose of the Study:

  • To highlight the elevated risk of coronary artery diseases in patients with diabetes.
  • To emphasize the link between glycemic control and cardiovascular complications.
  • To underscore the importance of managing comorbid conditions in diabetic cardiovascular disease prevention.

Main Methods:

  • Literature review on coronary artery disease prevalence in diabetic populations.
  • Analysis of studies correlating glycosylated hemoglobin (HbA1c) levels with cardiovascular event risk.
  • Examination of evidence supporting the preventive role of managing hyperglycemia, dyslipidemia, and hypertension.

Main Results:

  • Diabetic patients face a substantially higher risk of developing coronary artery diseases.
  • Higher glycosylated hemoglobin levels are directly associated with an increased likelihood of cardiovascular complications.
  • Effective management of hyperglycemia, dyslipidemia, and hypertension demonstrates a preventive effect against cardiovascular events.

Conclusions:

  • Aggressive management of hyperglycemia, dyslipidemia, and hypertension is crucial for preventing cardiovascular complications in diabetic patients.
  • Controlling key metabolic factors can mitigate the heightened cardiovascular risk associated with diabetes.
  • Integrated management strategies are essential for improving long-term outcomes in diabetic patients with or at risk for CAD.

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Related Concept Videos

Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...